Evidence of meeting #66 for Health in the 41st Parliament, 1st Session. (The original version is on Parliament’s site, as are the minutes.) The winning word was research.

A recording is available from Parliament.

On the agenda

MPs speaking

Also speaking

Andrew McKee  President and Chief Executive Officer, Juvenile Diabetes Research Foundation Canada
Deborah Sissmore  Ambassador, Juvenile Diabetes Research Foundation Canada
Michael Thornton  Ambassador, Juvenile Diabetes Research Foundation Canada
Noah Stock  Ambassador, Juvenile Diabetes Research Foundation Canada
Marley Greenberg  Ambassador, Juvenile Diabetes Research Foundation Canada
Miguel Rémillard  Ambassador, Juvenile Diabetes Research Foundation Canada
Maksim Stadler  Ambassador, Juvenile Diabetes Research Foundation Canada
Laurent Legault  Medical Doctor, Montreal Children's Hospital, McGill University, As an Individual
Jan Hux  Chief Scientific Advisor, National Office, Canadian Diabetes Association
Philip Sherman  Scientific Director, Institute of Nutrition, Metabolism and Diabetes, Canadian Institutes of Health Research
Jane Aubin  Chief Scientific Officer and Vice-President, Research and Knowledge Translation, Canadian Institutes of Health Research

11:50 a.m.

President and Chief Executive Officer, Juvenile Diabetes Research Foundation Canada

Andrew McKee

It would be speculation on my part—and I'm happy to try to speculate a little bit for you—but there are several companies working on it right now. Within JDRF trials and testing we have this working in a hospital environment, so in a very controlled environment.

The work that needs to be done is the clinical trials to test that in a broader market, a broader population, so the evidence-based medicine will be there to get approval from health regulators in Canada, western Europe, and the U.S.

The timeframe for bringing something like that from a clinical trial to test it out to the market can range anywhere from two years out to eight to 10 years, depending on whether any complications arise in that development. But there are versions of the artificial pancreas working today in a laboratory environment right now. So this now becomes a big question of commercialization and how you get it to market, and clinical trials are what we need to move those devices forward.

11:55 a.m.

Conservative

Wladyslaw Lizon Conservative Mississauga East—Cooksville, ON

Do I have any time left?

11:55 a.m.

Conservative

The Chair Conservative Joy Smith

You have less than a minute.

11:55 a.m.

Conservative

Wladyslaw Lizon Conservative Mississauga East—Cooksville, ON

Are there any new developments on the Edmonton Protocol? I understand there is a challenge with donors, but is there any new development with artificially growing the implants?

11:55 a.m.

President and Chief Executive Officer, Juvenile Diabetes Research Foundation Canada

Andrew McKee

Debbie is our resident expert; she's a living example of the Edmonton Protocol.

A number of advances have been made in the cell therapy arena in terms of the ability to regenerate insulin-producing cells outside of an individual. The traditional sources of cells are being looked at, which are the pancreases of cadaver donors. Stem cell work is being done around regenerating an individual's stem cells so their own stem cells could be reimplanted into them. The other area that's seeing a lot of investigation, and JDF is running some trials on this outside Canada—we aren't doing it in Canada—is core—

11:55 a.m.

Conservative

The Chair Conservative Joy Smith

Thank you, Mr. McKee. Thank you so much.

We don't have time to go into another round. The parents have requested a picture with the parliamentarians, and I think that's the least we could do. We'll have our guests sit, and I'll instruct you on how to do that picture in a minute.

Dr. Sellah, you had a comment.

11:55 a.m.

NDP

Djaouida Sellah NDP Saint-Bruno—Saint-Hubert, QC

Thank you, Madam Chair.

I am very proud of the young people of today. To me, you are superheroes, as Mr. Noah Stock was saying. I know that type 1 diabetes is an autoimmune disease. So you have no responsibility to bear in that regard. However, you are aware of your disease and you try to lead as normal a life as your friends do. You lead your young persons' lives, but I would say to you that as long as there is life, there is hope. I want to congratulate you because you are an example, you are the future of our country.

As a general practitioner, I think that you are in a better position than certain adults who have another type of diabetes that is due, for instance, to their lifestyle. I want to encourage you to continue what you are doing. You saw, with the example Ms. Sissmore gave, that with the evolution of technology, we have come up with the insulin pump rather than insulin injected with sterile glass syringes.

And so, I can only congratulate you. Continue your struggle. Congratulations.

11:55 a.m.

Conservative

The Chair Conservative Joy Smith

Thank you, Dr. Sellah.

Dr. Sellah is a medical doctor, so that's quite a compliment to all of you.

We're going to do something a little different. I'm going to suspend the committee for 10 minutes, because we have to bring on another panel at precisely five after twelve.

Your parents have requested that we have a picture with the parliamentarians. I would suggest that you stay seated and the parliamentarians will be very good at clustering around. The parents can come inside—there's a little opening in there—to take your pictures.

We'll suspend for 10 minutes.

12:07 p.m.

Conservative

The Chair Conservative Joy Smith

Could we reconvene again?

We had a very exciting panel with some young witnesses who gave us a clear insight into what it's like to live with type 1 diabetes.

We have a second panel now, and we have from the Canadian Diabetes Association, Dr. Jan Hux, who is going to be the first....

Pardon me?

Is Dr. Legault here? Oh, it's by video conference. Dr. Legault, I understand that you're on call right now and you need to leave shortly, so we'll begin with you.

12:07 p.m.

Dr. Laurent Legault Medical Doctor, Montreal Children's Hospital, McGill University, As an Individual

That would be appreciated.

12:07 p.m.

Conservative

The Chair Conservative Joy Smith

Thanks to the clerk, I'm informed of your busy schedule, Dr. Legault. Welcome, and thank you so much.

Please begin.

12:07 p.m.

Medical Doctor, Montreal Children's Hospital, McGill University, As an Individual

Dr. Laurent Legault

Thank you. I sent over my text, I believe.

Dear members, I was approached a couple of weeks ago to present to the committee. Initially, I was told that the committee would like to hear about my perspective on what should be the priorities in the field of juvenile diabetes, specifically outlining the potential role of public health. You may then excuse me if my comments sound quite different from those of other presenters. Given that JDRF, CIHR, and the CDA will also be represented at this committee, I don’t intend to put much emphasis on research that I or my colleagues are undertaking, even though I strongly feel that supporting research that aims to prevent diabetes and to alleviate the burden of injecting multiple times daily for these children should be priorities. I reserve my comments on these issues for the question period.

I also acknowledge that my perspective is heavily biased by my working environment and may not reflect the reality of others.

Finally, I am well aware that this is a federal committee and that health coverage is a provincial matter, so there are limits to what can be accomplished.

For starters, the first point I’d like to make is that juvenile diabetes is now a much more confusing term. Type 2 diabetes, which gets a lot of media coverage, has been steadily increasing in our clientele. This entity—as well as cystic fibrosis-related diabetes and genetic forms—has made diabetes care much more complex and diversified in the pediatric age range.

It is also important to note that while there is no doubt type 2 diabetes prevalence is increasing, it has not reached the epidemic proportions it has in the United States, and it still represents a small proportion of most of the country’s diabetes clinic populations. It is nevertheless concerning to see it growing. While both type 1 and type 2 diabetes have been increasing in most industrialized countries, it is still quite difficult to have good data to support this claim in Canada. Estimates of prevalence and incidence are usually given, but are mostly based on partial or unreliable data.

Canada has always been known to have a high incidence of type 1 diabetes, but proper ways to carefully follow trends and examine regional distribution of cases have been lacking. The creation of provincial or national registries has been plagued by many snags and is not usually a high priority for granting agencies struggling to maintain their budgets from year to year.

The setting of well-designed provincial and national registries would allow us to follow these trends, properly delineate diabetes type—and I admit that this is a challenging task—and help properly distribute care amongst areas according to the disease burden. An active diabetes registry for type 2 diabetes could allow, for instance, reflecting on the impact of interventions designed to curtail the increase of cases over time, not to mention its immense potential in the field of research to explore links to a yet elusive trigger for diabetes emergence.

We are now quite adept at predicting type 1 diabetes emergence in high-risk individuals based on our long-standing experience in prevention studies like DPT and others, but have yet to find a strategy to stop type 1 diabetes in its tracks. While we all wait and hope that some of these studies, one of which I am part of, pan out, there is a need to make sure that we diagnose those children who develop type 1 diabetes early.

The proportion of cases being diagnosed in diabetes ketoacidosis, also known as DKA, is still unacceptably high for a country where medical access should be universally accessible. The Province of Ontario explored this, and a campaign of information designed to remind key stakeholders of the early clinical signs of diabetes—frequent urination, thirst, weight loss—has been designed to address this issue.

Pushing this further, I’d advocate that information, as well as providing access to quick and useful diagnostic tools, such as urine dipsticks, glucometers in clinics and other care settings, to avoid the undue delay of sending out to labs and waiting three to five days for results to come back, would be a small investment with potentially huge dividends.

It is paramount that caregivers and others involved in the care of children understand the nature of type 1 diabetes. Those three to five days can make all the difference between a child's being started on insulin and going home the same day and an intensive care admission, cerebral edema, and unfortunately, but rarely, death.

While it is common to explore the diagnosis of type 2 diabetes over several weeks, timing is crucial for type 1 diabetes. This semantic point is not trivial, as diabetes is plagued by the fact that most people are familiar with type 2, and in a lumping culture—in other words, “all diabetics are the same”—the image of diabetes that most people, including health workers, have and sometimes transmit is tainted by this reality: “It has to be type 2; there are no other kinds.”

This impacts upon the care of those, mostly children, affected by type 1 diabetes. A concerted effort to extend to the rest of the country initiatives aimed at diagnosing cases early would seem to represent an excellent cost benefit.

Diabetes management has become much more complex with the advent of new insulin options and the insulin pump. You heard something about it earlier. Several provinces now have a reimbursement program that allows interested families to benefit from this technology. While these provincial efforts are acknowledged and welcomed, the human factor has unfortunately fallen short. There is a wide discrepancy in services provided in schools for these children.

More specifically, there is a need for more support in elementary schools and day care centres. The growing perception is that these technologies do everything, but they fail to understand that a six-year-old child should not be expected to be fully in charge of what is basically a mini-computer. I am aware of several families in which one of the parents had to stop working or cut back on work hours to personally supervise their child at lunchtime because school personnel refused to do it. I personally think this is unacceptable. The same situation could arise in the case of intensive insulin regimens that incorporate lunchtime injections.

It is extremely challenging to find a working collaboration in many schools across the country. Every child, including those with a chronic medical condition, has a right to be educated, but implementing this principle in the school setting is not always easy. Diabetes teams frequently team up with school resources to ensure the best possible environment for the type 1-affected child, but nursing training and availability are lacking or inappropriate, and quality of care is then affected. Strong leadership by diabetes organizations is important to make schools more diabetes-friendly.

There is also a wide disparity in coverage of basic material for daily diabetes care. Just as an example, strips for glucometers are not covered in every province. I am well aware that health coverage is a provincial mandate, but I cannot stand idle when I hear that some families struggle to pay for their glucometer strips—or any essential material, for that matter, for the safety and care of their children. A federal program aimed at ensuring a minimum basic coverage of material for this and other chronic diseases would seem an important safety net to ensure that families do not run short of material because they can’t afford it. These potential inequities are unacceptable.

Along the same lines, providing safe and adequately staffed summer camps for children with special needs—and that includes any with chronic disease—should not have to entirely depend on private foundations' support. I know that CDA is supporting many, and we are grateful for that, but many camps just get by and struggle. All families should have access to these stimulating and potentially life-changing environments. To ensure access to these camps for all children regardless of their socio-economic background, extra support should be provided.

Focusing now on type 2 diabetes, we know that its prevention is possible. Given its strong link with pediatric obesity and its known concentration in lower socio-economic strata of our society, I strongly believe that the fight against a potential type 2 diabetes epidemic in children is akin to the fight against poverty and hence mandates a concerted effort on multiple fronts.

More specifically, there is a lack of affordable and accessible opportunities for exercise outside of school for families from low socio-economic areas. School game and exercise facilities are underused and could be made available for after-school programs with the help of a kinesiologist trained to adapt the programs to the level of fitness of the children he or she faces.

There's also a need for adequate counselling, based on the financial constraints many of these families face, from a nutritionist trained in pediatrics, and I insist on this. Availability of good counselling is a big challenge in the hospital setting because of budgetary constraints. Community-based nutrition counselling is for the most part targeted to the adult clientele. There is a gap that is disfavouring the more vulnerable.

I personally don’t favour taxing fast food, but rather subsidizing healthy foods—

12:20 p.m.

Conservative

The Chair Conservative Joy Smith

Dr. Legault, I'm sorry to interrupt you, but we've gone quite a bit over time. It's so interesting. Could you just please summarize so that we get all your points in?

Thank you so much.

12:20 p.m.

Medical Doctor, Montreal Children's Hospital, McGill University, As an Individual

Dr. Laurent Legault

Okay. I'm sorry; I didn't look at the time.

Summarizing, we need to try to prevent type 2 diabetes using school as the pivotal place to do so. I think we need to make sure that everybody has access to the material that's necessary to take care of diabetes in the 21st century. We need school support for patients who are trying to make their diabetes treatment intensive, whether through injections or through a pump.

I think I'll stop with that.

12:20 p.m.

Conservative

The Chair Conservative Joy Smith

Thank you so much.

Some of the points you made were very good ones. As a former school teacher, I too was baffled that all these facilities were empty. That is a very good point.

We'll now go on to Dr. Hux, chief scientific advisor to the Canadian Diabetes Association.

12:20 p.m.

Dr. Jan Hux Chief Scientific Advisor, National Office, Canadian Diabetes Association

Good afternoon. On behalf of the Canadian Diabetes Association, thank you for this opportunity to speak with you about juvenile diabetes.

The Canadian Diabetes Association is a leading authority on diabetes in Canada and internationally. We lead the fight against diabetes by helping people with the disease live healthy lives while we search for a cure. By providing education and services, advocating on behalf of people with diabetes, supporting research and translating research into practical applications, we deliver on our mission.

Type 1 diabetes is a disease in which the pancreas produces little or no insulin. As you've heard from other witnesses, this results in high blood sugar that requires lifelong insulin therapy administration by injection, and attention to diet and physical activity to maintain appropriate blood glucose levels. These measures are essential to prevent acute life-threatening emergencies due to excessively high or low blood glucose.

However, even moderately high blood glucose levels over a long period of time are dangerous because they lead to the chronic complications of diabetes, including kidney failure, heart attack, blindness, stroke, limb amputation, and depression. The average life expectancy for people with type 1 diabetes may be shortened by as much as 15 years.

Type 1 represents up to 90% of cases in people under the age of 20 and up to 10% of the overall population with diabetes, or about 300,000 Canadians.

While research is making great strides, at present there is no cure.

I would now like to address two important gaps in the care available for children with type 1 diabetes: a safe and supportive school environment, and appropriate access to insulin pumps. Children with type 1 diabetes must pay close attention to their diet and physical activity, regularly test their blood glucose levels, calculate insulin dosages, and administer insulin. This can be challenging, especially for young children. Excessively high blood sugar can interfere with students' ability to participate in school and excessively low blood sugar can quickly turn into a life-threatening emergency.

Students with diabetes must be full participants in school life. To ensure a safe school environment, every school board should have a diabetes policy that requires development of an individualized care plan for each student with diabetes. The plan would identify the type of care and monitoring required by the students to successfully manage their diabetes while attending school or related activities.

A diabetes policy should include strategies to reduce the incidence of high and low blood glucose, a communication plan, and regular diabetes training for school personnel. School boards should be responsible for ensuring that students with diabetes receive the care they require, including medication administration and blood glucose testing.

I would now like to turn to the benefits of insulin pumps to manage type 1 diabetes. These are portable devices attached to the body that deliver a constant baseline amount of insulin as well as bolus doses at meal times via a small tube placed under the skin.

Research supports the medical benefit of pumps versus multiple daily injections of insulin where clinically appropriate. The use of a pump has been shown to improve average blood glucose levels and consequently will, over the long term, reduce complications for those with type 1 diabetes.

In response to efforts by our association, insulin pump programs have been announced, implemented, or enhanced in several provinces. As a result, those with type 1 diabetes who require pumps will have better quality of life, and these provinces will also reduce their health care costs associated with diabetes. Insulin pumps are also available in aboriginal populations through special authorizations administered through federal non-insured health benefits. However, some provinces still have no comprehensive program for coverage. The existing programs in Canada serve only 30% to 35% of eligible persons. Savings from reduced complications are estimated to exceed the costs of implementing these programs in each jurisdiction.

While we seek to ensure that people with diabetes have access to the best available treatments, we also see the critical need for better treatments, and ultimately for a cure. Accordingly, we invest in the creation of new knowledge through research.

As Canada's leading diabetes charity, last year we devoted $7.1 million to fund 111 research projects. Since 1975 we've invested over $110 million to fund research to reduce the burden of diabetes, improve the health of people with the disease, and find a cure.

Some leading-edge examples include the following.

Dr. Pere Santamaria’s therapeutic nanovaccine halts the autoimmune attack that causes type 1 diabetes without impairing the ability of the immune system to respond to infections and cancer.

Dr. Julie Lavoie's anti-obesity drug may reduce weight gain in the obese and bring blood glucose levels close to those of people of normal weight.

Researcher, Dr. Przemyslaw Sapieha, has identified a molecule responsible for the leaking of blood vessels in the diabetic eye; such leakage often causes vision loss.

One research project often builds upon the next and requires collaboration between multiple funders. For example, Canada’s first successful islet cell transplant was conducted in 1991 by Dr. Garth Warnock. Building on his work, a University of Alberta team of researchers, several funded by our association, announced a breakthrough technique for islet cell transplantation for severe type 1 diabetes. By increasing the success of transplants, our funding has supported a milestone in the search for a cure.

I would now like to conclude my remarks with a brief mention of the link between childhood obesity and the significant increase in type 2 diabetes in North American children over the past two decades.

The link between unhealthy weights and type 2 diabetes is clear. Since almost two-thirds of Canadian adults and almost one-third of Canadian children and youth are overweight or obese...if these rates remain constant, the prevalence of diabetes will keep climbing.

In your 2007 report on childhood obesity, this committee shared the “...fears of many experts who predict that today’s children will be the first generation for some time to have poorer health outcomes and a shorter life expectancy than their parents.” Our association shares this concern.

Individual and community solutions are available to achieve healthy weights. It is estimated that over 50% of type 2 diabetes could be prevented or delayed with healthier eating and increased physical activity. Weight loss of 5% to 10% has been shown to reduce the risk of diabetes.

Ladies and gentlemen, thank you again for this opportunity to share this important information. I would be pleased to answer your questions.

12:25 p.m.

Conservative

The Chair Conservative Joy Smith

That's some very interesting information. It sounds like it's possible to get to this type 2 diabetes through diet. We'll talk more about that.

We'll now go to the Institute of Nutrition, Metabolism and Diabetes. Dr. Sherman, please.

12:25 p.m.

Dr. Philip Sherman Scientific Director, Institute of Nutrition, Metabolism and Diabetes, Canadian Institutes of Health Research

Thank you for this opportunity to speak about the Canadian Institutes of Health Research and our support of diabetes research in Canada to mark Diabetes Awareness Month.

I am the scientific director of the CIHR Institute of Nutrition, Metabolism and Diabetes, and I'm a staff pediatrician gastroenterologist at the Hospital for Sick Children in Toronto. I am also a professor of pediatrics, microbiology, and dentistry at the University of Toronto.

I am pleased to be joined here today by my colleague, Dr. Jane Aubin, the vice-president and chief scientific officer of the CIHR.

Diabetes research is central to the mandate our institute. Echoing the pioneering spirit of Dr. Banting and Dr. Macleod, many contemporary Canadian researchers are recognized internationally for their important studies related to advancing knowledge about the basic mechanisms and optimum interventions to manage diabetes.

The Chief Public Health Officer of Canada reported that in 2008 roughly 2.4 million Canadians, or nearly 7% of all Canadians, were living with diabetes. It is estimated that about 10% of those have type 1 diabetes. The per capita health care costs are four times greater for populations affected by diabetes, compared with those without the illness. There are limitations on the data, as you heard from Dr. Hux, but among aboriginal peoples it is estimated that the prevalence of diabetes, whether they live on or off reserve, is higher compared with rates in non-aboriginal populations. In general, aboriginal individuals are diagnosed with diabetes at a younger age and suffer from more severe complications of the illness.

CIHR is the Government of Canada funder of health research for all types of diabetes and its long-term complications, which you heard Dr. Hux mention. CIHR funds the gamut of research, including discovery-based research, clinical research, health services research, and population-based research.

Since 2006, CIHR has committed nearly $250 million to support diabetes-related research, which benefits all affected individuals, because the knowledge gained is often highly transferable between the different types of diabetes. CIHR has also made substantial investments in obesity-related research, as obesity is a key risk factor for type 2 diabetes.

Examples of diabetes research that CIHR has supported include the following.

There is research on developing a new way of using gene therapy to deliver cells produced inside the body, instead of using an insulin pump on the outside, and to detect glucose levels in the blood. That pioneering work is done at the University of British Columbia, funded by CIHR.

Dan Drucker, at the University of Toronto, won the CIHR/Canadian Medical Association top achievements in health research award last year for his work on new peptides, which has led to the development of whole new classes of drugs in the treatment of diabetes.

CIHR also funds studies looking at Smartphone technologies to care for diabetics in remote, rural communities, like the far north, to better manage their disease and the complications arising from it.

An important study funded by CIHR and JDRF is the first prevention trial in the world for type 1 diabetes. It's looking at genetically susceptible individuals. You heard the young lady whose mother had diabetes. Well, that individual is being entered into trials at birth to see if adjustments in the diet can prevent or delay the onset of type 1 diabetes. That study is now being undertaken, and we won't know the results for another five years, but that's the kind of work that CIHR is funding.

CIHR also supports larger signature initiatives in priority-need areas, where Canada can capitalize on our strengths and excellence, including in the area of diabetes. For example, $25 million has been committed by CIHR for Pathways to Health Equity for Aboriginal Peoples, and this includes a focus on obesity and diabetes. A second signature initiative in inflammation and chronic disease focuses on this critical component in the development of multiple chronic diseases, including both type 1 and type 2 diabetes. A third signature initiative focuses on the epigenetic impact on chronic diseases like diabetes, and a fourth looks at managing diabetes in primary health care settings, including rural and remote communities.

CIHR now is strongly supporting a strategy for patient-oriented research to ensure the translation of new knowledge to point-of-care therapy in provinces and territories. This is meant to help them meet the challenges of delivering high-quality, cost-effective health care for specific identified needs.

We anticipate that these new research initiatives and their findings will lead to improved prevention and treatment for Canadians with diabetes.

In addition, we are launching research funding initiatives that will further support diabetes research. For instance, we recently launched a $10 million funding research opportunity to support comprehensive programs of research in the area of food and health. This funding will support research to better understand how diet and dietary factors impact on chronic disease.

Another initiative we'll soon launch supports the research on the environment, genes, and their impact on chronic disease, like diabetes. Advances in gene therapy, cell transplantation, patient-based research, new technologies, and improvements to health care service delivery will effectively be used to manage, prevent, or delay the onset of diabetes in the future.

With that, I conclude my comments. Dr. Aubin and I would be pleased to take your questions, comments, and feedback.

Thank you very much.

12:30 p.m.

Conservative

The Chair Conservative Joy Smith

Thank you very much for all your insightful comments, Dr. Sherman, Dr. Legault, and everybody who has been here today.

We'll now go to our seven-minute Q and A round. I understand Dr. Sellah and Ms. Davis are sharing their time, so we'll begin with Dr. Sellah.

12:35 p.m.

NDP

Djaouida Sellah NDP Saint-Bruno—Saint-Hubert, QC

Thank you, Madam Chair.

I am going to get directly to the point.

First of all, I want to thank all of the witnesses here for having provided us with this more up-to-date information.

My question is for Dr. Legault.

At the beginning of your presentation, you said that there were provincial and national registries, but that unfortunately the system had some snags. Could you explain what you meant by that?

12:35 p.m.

Medical Doctor, Montreal Children's Hospital, McGill University, As an Individual

Dr. Laurent Legault

In fact, my point was not that we had some, but rather that we would like to see some well-designed registries.

12:35 p.m.

NDP

Djaouida Sellah NDP Saint-Bruno—Saint-Hubert, QC

Oh! I apologize.

12:35 p.m.

Medical Doctor, Montreal Children's Hospital, McGill University, As an Individual

Dr. Laurent Legault

It is a difficult task, because the delineation of type 2 and type 1 diabetes is very difficult. There are registries. I know the Ontario one. However, the definition of cases is such that it is really quite difficult to tell whether one is dealing with type 1 or type 2 diabetes.

Before, it used to be easy. We used to say that an adult had type 2, and a child had type 1. However, now that we know that type 2 diabetes is emerging among children, and that type 1 diabetes can be diagnosed in patients of 20 or 30, the picture is much more confusing. Consequently it is more difficult to determine the real needs and trends.

There is a global increase in the incidence of type 2 diabetes, but also of type 1. The latter is increasing especially among very young children, those of less than 5 or 6. We hear that the situation is the same everywhere, but this is often based on data from clinics in large centres such as Toronto or Montreal, where the Sainte-Justine hospital is located. So that gives us a much vaguer picture of the situation.

I think there would be a lot of advantages to having well-kept registries that would allow us, as is the case for instance in Scandinavia, to see exactly what is being done, while reporting the distribution of cases. Diabetes is also found in rural areas, as well as in urban areas, although there are many more cases in urban areas. Consequently, the health needs of people who live in those areas are greater. We could then distribute health care according to the real prevalence of the disease.

12:35 p.m.

NDP

Djaouida Sellah NDP Saint-Bruno—Saint-Hubert, QC

Thank you.

How much time do I have left, Madam Chair?

12:35 p.m.

Conservative

The Chair Conservative Joy Smith

You have about three more minutes.